We found a match
Your institution may have access to this item. Find your institution then sign in to continue.
- Title
Interim analyses of the multinational real‐world prospective cohort HEM‐POWR study evaluating the effectiveness and safety of damoctocog alfa pegol in patients with hemophilia A.
- Authors
Reding, Mark T.; Álvarez‐Román, María Teresa; Castaman, Giancarlo; Janbain, Maissaa; Matsushita, Tadashi; Meijer, Karina; Schmidt, Kathrin; Oldenburg, Johannes
- Abstract
Objectives: To assess effectiveness and safety of damoctocog alfa pegol in interim analyses of the ongoing real‐world hemophilia A HEM‐POWR study. Methods: HEM‐POWR (NCT03932201) is a multinational Phase 4 prospective observational study. The primary objective was annualized bleeding rate (ABR) in previously treated patients (PTPs) with hemophilia A. Secondary objectives included adverse events and number of affected joints. Results: At data cut‐off (August 17, 2022), the safety analysis set included 268 patients and the full analysis set (FAS) included 161 patients. The most common dosing regimen during observation period was prophylaxis (FAS = 158/161, 98.1%) every 3–4 days (twice weekly; FAS = 78/158, 49.4%) and a median (min, max) infusion dose of 37.5 (10, 72) IU/kg. PTPs receiving prophylactic damoctocog alfa pegol have fewer infusions compared with prior treatment. Median total ABR (Q1, Q3) was 0.0 (0.0, 1.8) and mean total ABR (SD) was 2.4 (8.2). The proportion of patients with no affected joints increased between initial visit and follow‐up. No FVIII inhibitors, treatment‐related adverse events, or deaths were reported. Conclusions: Damoctocog alfa pegol shows effectiveness and acceptable safety, as well as consistent utilization, in real‐world PTPs with hemophilia A, including in patients with non‐severe hemophilia and those with a history of inhibitors. Please see video for a summary of this study.
- Subjects
HEMOPHILIACS; BLOOD coagulation factor VIII antibodies; ADVERSE health care events; HEMOPHILIA; COHORT analysis
- Publication
European Journal of Haematology, 2024, Vol 112, Issue 2, p286
- ISSN
0902-4441
- Publication type
Article
- DOI
10.1111/ejh.14114